Skip to main content

Comera Life Sciences Holdings, Inc.

CMRADelisted Feb 15, 2024
Industry
Pharmaceutical Preparations
SEC CIK
0001907685

Comera Life Sciences Holdings, Inc. was delisted on Feb 15, 2024; its insiders filed their last Form 4 on Feb 2, 2024; 14 institutions reported holding it in 13F filings for Q3 2023, worth $194.1K in total; no superinvestor held it.

Key figures

Market cap
–
Not available
Insider buys
0
Open market, last 90 days
Insider sells
0
Open market, last 90 days
13F holders
14
Q3 2023, +3 vs. previous quarter
13F value
$194.1K
Reported value at the end of Q3 2023
Superinvestors holding
0
At the end of Q3 2023

From SEC filings, in USD.

Revenue, FY2022
$633.1K
No comparable prior period
Net income, FY2022
-$18.0M
No comparable prior period
Free cash flow, FY2022
-$9.80M
No comparable prior period
Revenue, Q3 FY2023
$136.3K
−42.0% year over year

Revenue flow, FY2022

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2022: $18.0M (2843.8% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
4.33K
Shares sold short
Change
0
0.0% vs. previous
Days to cover
123.63
At average daily volume

Superinvestors holding CMRA, Q3 2023

Go to the superinvestors tab

No superinvestor reported holding CMRA at the end of Q3 2023.

Latest insider trades

See all insider trades

Open-market purchases and sales by Comera Life Sciences Holdings, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Feb 2, 2024 (view filing)7:48 PM ETDec 29, 202335 daysLateKonar Shameek and 1 otherOther: Member of 10% owner groupPPurchase+6.14M$0.00$0–4.09M afterDerivative2 lotsPrice outlier
Jan 11, 2024 (view filing)7:14 PM ETDec 29, 202313 daysLateDenny George P IIIOther: Member of 10% owner groupPPurchase+5.87M$0.00$0–3.91M afterDerivative2 lotsPrice outlier
Jan 5, 2024 (view filing)5:59 PM ETDec 29, 20237 daysLateIaf, LLCOther: Member of 10% owner groupPPurchase+11.5M$0.00$0–7.64M afterDerivative2 lotsPrice outlier
Jan 3, 2024 (view filing)8:38 PM ETDec 29, 20235 daysCherington Charles10% OwnerPPurchase+31.0M$0.00$0–20.7M afterDerivative2 lotsPrice outlier
Jan 3, 2024 (view filing)8:38 PM ETDec 27, 20237 daysLateCherington Charles10% OwnerPPurchase+310.2K$6,280.01+$1.95B–3.90K afterDerivativePrice outlier
Jan 3, 2024 (view filing)8:09 PM ETDec 29, 20235 daysHuff Curtis W and 2 others10% OwnerPPurchaseCommon Stock, par value $0.0001 per share+7.36M$0.055+$134.9K–7.36M afterDerivative2 lots
Jan 3, 2024 (view filing)6:30 PM ETDec 29, 20235 daysSoane David and 1 other10% OwnerPPurchase+8.18M$25,000.00+$204.5B–2.73M afterDerivative4 lotsPrice outlier
Nov 28, 2023 (view filing)4:25 PM ETNov 271 dayCampbell Michael GerardEVP & CFOPPurchase+10.0K$0.0708+$708+40.0%35.0K after
Sep 12, 2023 (view filing)4:52 PM ETSep 111 daySoane David and 1 other10% OwnerPPurchase+117.4K$0.5112+$60.0K+70.3%284.3K after2 lots
Sep 12, 2023 (view filing)4:52 PM ETSep 111 daySoane David and 1 other10% OwnerPPurchase+293.4K$0.00$0–146.7K afterDerivative2 lots

Top 10 13F holders, Q3 2023

See all 14 holders

The largest institutional positions in Comera Life Sciences Holdings, Inc. at the end of Q3 2023; share changes are against Q2 2023.

Institutions holding CMRA in Q3 2023
InstitutionSharesValue% of portfolioChange in sharesAction
CI Private Wealth, LLC493,692$123.4K0.00%+493,692New
Geode Capital Management, LLC70,212$22.4K0.00%+10,204+17.0%Added
HighTower Advisors, LLC47,600$14.0K0.00%00.0%Unchanged
Vanguard Group Inc44,098$12.9K0.00%00.0%Unchanged
State Street Corp29,600$9.44K0.00%00.0%Unchanged
Citadel Advisors LLC17,458$5.57K0.00%+17,458New
UBS Group AG8,017$2.33K0.00%+6,366+385.6%Added
Tower Research Capital LLC (TRC)7,338$2.14K0.00%−24−0.3%Reduced
Advisor Group Holdings, Inc.3,600$1.05K0.00%−15,150−80.8%Reduced
Morgan Stanley2,292$6680.00%00.0%Unchanged